NASDAQ:CPRX - Catalyst Pharmaceuticals Stock Price, News & Analysis

$6.57
+0.03 (+0.46 %)
(As of 09/19/2019 04:00 PM ET)
Today's Range
$6.43
Now: $6.57
$6.65
50-Day Range
$4.91
MA: $5.87
$7.62
52-Week Range
$1.85
Now: $6.57
$7.67
Volume943,700 shs
Average Volume1.94 million shs
Market Capitalization$676.68 million
P/E RatioN/A
Dividend YieldN/A
Beta2.38
Catalyst Pharmaceuticals, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with lambert-eaton myasthenic syndrome in the United States. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CPRX
CUSIPN/A
Phone305-420-3200

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$500,000.00
Book Value$0.49 per share

Profitability

Net Income$-34,000,000.00

Miscellaneous

Employees51
Market Cap$676.68 million
Next Earnings Date11/6/2019 (Estimated)
OptionableOptionable

Receive CPRX News and Ratings via Email

Sign-up to receive the latest news and ratings for CPRX and its competitors with MarketBeat's FREE daily newsletter.


Catalyst Pharmaceuticals (NASDAQ:CPRX) Frequently Asked Questions

What is Catalyst Pharmaceuticals' stock symbol?

Catalyst Pharmaceuticals trades on the NASDAQ under the ticker symbol "CPRX."

How were Catalyst Pharmaceuticals' earnings last quarter?

Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) issued its quarterly earnings results on Wednesday, August, 7th. The biopharmaceutical company reported $0.10 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $0.03 by $0.07. The biopharmaceutical company had revenue of $28.84 million for the quarter, compared to analysts' expectations of $17.99 million. The company's revenue was up 2883900.0% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.06) EPS. View Catalyst Pharmaceuticals' Earnings History.

When is Catalyst Pharmaceuticals' next earnings date?

Catalyst Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, November 6th 2019. View Earnings Estimates for Catalyst Pharmaceuticals.

What price target have analysts set for CPRX?

5 brokers have issued 1-year price objectives for Catalyst Pharmaceuticals' stock. Their predictions range from $6.00 to $12.00. On average, they anticipate Catalyst Pharmaceuticals' stock price to reach $9.10 in the next twelve months. This suggests a possible upside of 38.5% from the stock's current price. View Analyst Price Targets for Catalyst Pharmaceuticals.

What is the consensus analysts' recommendation for Catalyst Pharmaceuticals?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Catalyst Pharmaceuticals in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Catalyst Pharmaceuticals.

What are Wall Street analysts saying about Catalyst Pharmaceuticals stock?

Here are some recent quotes from research analysts about Catalyst Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Catalyst's Firdapse is the company’s first approved product. The drug is the first FDA-approved treatment for Lambert-Eaton Myasthenic Syndrome (LEMS) in adults, which was approved in November 2018 and launched in January. The company generated entire first-quarter revenues from Firdapse. Catalyst is also developing Firdapse to treat additional rare neuromuscular diseases. However, all the other candidates in its portfolio are in early stages of development. Thus, the successful development and commercialization of drug candidates are highly crucial for the company. Shares of the company have outperformed the industry year to date. Estimates have remained stable ahead of the Q2 results. The company has a mixed record of earnings surprises in the recent quarters." (7/31/2019)
  • 2. Cantor Fitzgerald analysts commented, ". We reiterate our Overweight rating and PT of $10 per share of CPRX. the FDA approved private company the treatment of LEMS in pts 6 to <17 years of age. This is the first drug approved for pediatric LEMS. However, Catalyst's slighty different salt form of amifampridine, marketed as Firdapse, was the first drug approved for LEMS, but for adults only. We were surprised by this announcement as no clinical studies were conducted in the pediatric population that we are aware of, and the approval relied on studies of the drug in adults with LEMS, including PK data that were then modeled/extrapolated to identify the dosing regimen in pediatric pts."" (5/7/2019)
  • 3. HC Wainwright analysts commented, "We raised our PT to $9 from $6 in view of the additional color on the commercial front. We adjusted the launch cost of and lowered the peak penetration from 25% to 18%." (12/14/2018)

Has Catalyst Pharmaceuticals been receiving favorable news coverage?

News headlines about CPRX stock have been trending negative on Thursday, according to InfoTrie Sentiment Analysis. The research firm identifies negative and positive media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Catalyst Pharmaceuticals earned a news impact score of -2.9 on InfoTrie's scale. They also gave media headlines about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the company's share price in the next few days. View News Stories for Catalyst Pharmaceuticals.

Who are some of Catalyst Pharmaceuticals' key competitors?

What other stocks do shareholders of Catalyst Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Catalyst Pharmaceuticals investors own include Novavax (NVAX), Synergy Pharmaceuticals (SGYP), SLS International (SLS), Cognex (CGNX), Verastem (VSTM), Amarin (AMRN), Exelixis (EXEL), Corbus Pharmaceuticals (CRBP), Micron Technology (MU) and AcelRx Pharmaceuticals (ACRX).

Who are Catalyst Pharmaceuticals' key executives?

Catalyst Pharmaceuticals' management team includes the folowing people:
  • Mr. Patrick J. McEnany, Co-Founder, Chairman, Pres & CEO (Age 72)
  • Ms. Alicia Grande, VP, Treasurer & CFO (Age 48)
  • Dr. Steven R. Miller, COO & Chief Scientific Officer (Age 57)
  • Mr. Brian Elsbernd, Chief Legal & Compliance Officer (Age 55)
  • Dr. Gary Ingenito, Chief Medical Officer & Head of Regulatory Affairs (Age 63)

Who are Catalyst Pharmaceuticals' major shareholders?

Catalyst Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.85%), Vanguard Group Inc. (4.72%), Morgan Stanley (2.45%), Northern Trust Corp (1.12%), JPMorgan Chase & Co. (0.93%) and Gables Capital Management Inc. (0.47%). Company insiders that own Catalyst Pharmaceuticals stock include Charles B O'keeffe, Donald A Denkhaus and Patrick J Mcenany. View Institutional Ownership Trends for Catalyst Pharmaceuticals.

Which major investors are selling Catalyst Pharmaceuticals stock?

CPRX stock was sold by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, Royal Bank of Canada, Lido Advisors LLC, Strs Ohio, Commonwealth Equity Services LLC, BNP Paribas Arbitrage SA and Tanaka Capital Management Inc.. View Insider Buying and Selling for Catalyst Pharmaceuticals.

Which major investors are buying Catalyst Pharmaceuticals stock?

CPRX stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Prudential Financial Inc., AQR Capital Management LLC, Morgan Stanley, Bank of America Corp DE, Swiss National Bank, Chicago Equity Partners LLC and ClariVest Asset Management LLC. Company insiders that have bought Catalyst Pharmaceuticals stock in the last two years include Charles B O'keeffe, Donald A Denkhaus and Patrick J Mcenany. View Insider Buying and Selling for Catalyst Pharmaceuticals.

How do I buy shares of Catalyst Pharmaceuticals?

Shares of CPRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Catalyst Pharmaceuticals' stock price today?

One share of CPRX stock can currently be purchased for approximately $6.57.

How big of a company is Catalyst Pharmaceuticals?

Catalyst Pharmaceuticals has a market capitalization of $676.68 million and generates $500,000.00 in revenue each year. The biopharmaceutical company earns $-34,000,000.00 in net income (profit) each year or ($0.33) on an earnings per share basis. Catalyst Pharmaceuticals employs 51 workers across the globe.View Additional Information About Catalyst Pharmaceuticals.

What is Catalyst Pharmaceuticals' official website?

The official website for Catalyst Pharmaceuticals is http://www.catalystpharma.com/.

How can I contact Catalyst Pharmaceuticals?

Catalyst Pharmaceuticals' mailing address is 355 ALHAMBRA CIRCLE SUITE 1250, CORAL GABLES FL, 33134. The biopharmaceutical company can be reached via phone at 305-420-3200 or via email at [email protected]


MarketBeat Community Rating for Catalyst Pharmaceuticals (NASDAQ CPRX)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  379 (Vote Outperform)
Underperform Votes:  215 (Vote Underperform)
Total Votes:  594
MarketBeat's community ratings are surveys of what our community members think about Catalyst Pharmaceuticals and other stocks. Vote "Outperform" if you believe CPRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CPRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 9/19/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel